We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Genetics and management of inherited cancer predisposition 1
- Prof. Joshua Schiffman
-
2. Genetics and management of inherited cancer predisposition 2
- Prof. Joshua Schiffman
-
3. The cytogenetics of childhood acute leukemia
- Dr. Susana C. Raimondi
-
4. Chromosome translocations and cancer
- Prof. Felix Mitelman
-
5. Acute myeloid leukemia: genetics, prognosis and treatments
- Prof. Stephen Nimer
-
6. Genetic abnormalities in acute lymphoblastic leukemia
- Prof. Ching Hon Pui
-
7. Molecular genetics of non-Hodgkin lymphoma
- Prof. Jude Fitzgibbon
-
8. Genetics of breast and ovarian cancer
- Prof. Jeffrey Weitzel
-
9. The genetics and genomics of familial renal carcinoma
- Prof. Eamonn Maher
-
10. Genomics of lung cancer
- Prof. Ramaswamy Govindan
-
11. The genetics of glioblastoma
- Dr. Hai Yan
-
12. Genetics of tumor metastasis 1
- Prof. Robert Weinberg
-
13. Genetics of tumor metastasis 2
- Prof. Robert Weinberg
-
14. CML: genetic paradigm of targeted therapy 1
- Prof. Michael W. Deininger
-
15. CML: genetic paradigm of targeted therapy 2
- Prof. Michael W. Deininger
-
16. The non-coding RNA revolution in the cancer society
- Prof. George Calin
-
17. Role of molecular markers in guiding therapy in cancer
- Prof. Joe Duffy
-
18. Functional cancer genomics
- Prof. Roderick Beijersbergen
-
19. Pharmacogenomics in cancer therapy
- Prof. Sharon Marsh
Printable Handouts
Navigable Slide Index
- Introduction
- Questions following a diagnosis of cancer
- Who to treat?
- Why we need prognostic markers
- Factors used in deciding on adjuvant therapy
- Current situation with prognostic markers
- Identifying patients for adjuvant systemic therapy
- Treatment of lymph node-negative breast cancer
- uPA/PAI-1: prognostic biomarker in breast cancer
- uPA/PAI-1: prognostic value
- Oncotype DX in lymph node breast cancer
- Oncotype DX to identify patients for chemotherapy
- Benefits of Oncotype DX
- Other prognostic signatures in breast cancer
- MSI in stage II colon cancer
- Stage II colon cancer
- MSI in stage II colon cancer: overview
- MSI in stage II colon cancer: benefits
- MSI in stage II colon cancer: chemotherapy
- MSI in stage II colon cancer: Lynch Syndrome
- AFP, HCG and LDH in metastatic germ cell cancers
- UICC classification for metastatic germ cell tumors
- How to treat?
- How to treat: predictive markers
- Systemic treatments for cancer
- Predictive markers: importance in cancer
- Response rates to therapy for advanced cancer
- Cost of targeted therapies
- The need for predictive markers
- Classical predictive markers
- ER as a predictive marker in breast cancer
- Importance of measuring ER
- ER and reduction in breast cancer mortality
- Patients likely to benefit from anti-HER2 therapies
- HER2 as a predictive marker in breast cancer
- Rationale for success of Herceptin in breast cancer
- HER2 importance: identifying response to Herceptin
- New anti-HER2 therapies
- Other therapy predictive markers
- EGFR mutations as markers
- EGFR mutations for predicting response to TKIs
- KRAS and NRAS mutations as markers
- EGFR antibodies for treatment of CRC
- Cetuximab & Panitumumab for treatment of CRC
- Predictive markers: gaps
- Predictive markers: responses
- Will the treatment cause severe toxicity?
- Toxicity markers
- How to determine if treatment is effective?
- Advantages of using markers vs. imaging
- Non-measurable disease
- Tumor markers potentially in monitoring therapy
- Caveats in use of markers in therapy
- Current vs. future approach to cancer management
Topics Covered
- Prognostic biomarkers in breast cancer
- Microsatellite instability (MSI) in colon cancer
- Markers for metastatic germ cell cancers
- Systemic treatments for cancer therapies
- Therapy predictive markers
- Toxicity markers
- Determining treatment effectivity
- Caveats in use of markers in therapy
- Current vs. future approach to cancer management
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Duffy, J. (2015, September 30). Role of molecular markers in guiding therapy in cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/XFQZ5790.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Joe Duffy has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Role of molecular markers in guiding therapy in cancer
Published on September 30, 2015
31 min
A selection of talks on Oncology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
My name is Professor Joe Duffy.
I work at St. Vincent's
University Hospital
and University College, Dublin.
The title of my presentation is
the Role of Molecular Markers
in Guiding Therapy in Cancer.
0:15
List some of the
questions that emerge
following a diagnosis of cancer.
The first question is who to treat?
In other words, which
patients, following
surgical removal of a
primary tumor, should receive
additional or adjuvant treatment?
If the decision is to treat,
the next question is how to treat?
In other words, what is the
most appropriate treatment
for a given patient?
Of a major concern to the
patient, is will the treatment
caused major toxicity?
And a fourth issue
is how to determine
if treatment is effective?
In other words, how to know
if the treatment is working?
The aim of this
lecture is to discuss
how molecular markers can help
address these four questions,
1:07
starting with who to treat.
Patients with aggressive
or life-threatening tumors
generally receive
adjuvant treatment.
On the other hand, patients
with indolent tumors
may be able to avoid having
to receive adjuvant treatment
and thus be spared from the
toxicity and costs of these drugs.
The distinction between
aggressive and indolent tumors
is aided by prognostic
markers or prognostic factors.
1:39
So why do we need
prognostic markers?
Well, prognostic markers
help avoid undertreatment
of aggressive tumors and
overtreatment of indolent tumors.